key: cord-0716512-ytoacwo4 authors: Riccetto, Eduardo; Ataide, Elaine Cristina; Perales, Simone Reges; Zanaga, Leticia; Ivano, Victor Kenzo; Ramalho, Juliana Elias; Colado, Talita; Stucchi, Raquel Silveira Bello; Boin, Ilka de Fátima Santana Ferreira title: Incidence and impact of COVID-19 cases in Brazilian liver transplant recipients - An academic, single-center experience date: 2022-04-22 journal: Transplant Proc DOI: 10.1016/j.transproceed.2022.03.046 sha: f6cd2156e6d139495e68422f873b5a50810fc6e5 doc_id: 716512 cord_uid: ytoacwo4 BACKGROUND Current literature reports diverge on the impact of COVID-19 in liver transplant (LT) recipients. Literature findings often report conflicting results, relying on small sample sizes, limited ethnic variability and non-standardized methodologies. Notably, there are no studies on this topic regarding Latin-American populations. This study seeks to report the impact of COVID-19, disease characteristics, and progression in LT recipients in a Latin-American academic center environment. METHODS The study design was a historic cohort, including adult LT recipient patients with suspected or confirmed COVID-19 who sought care between December 2019 to October 2021. Primary endpoint was defined as COVID-related death. Demographic, clinical, and laboratory data was also collected. RESULTS Twenty-seven patients were included, representing an 3,5% incidence within 752 patients in follow-up. The mean age and years from transplantation were 54 (+/- 11) and 6.3 years (SD +/- 5.4), respectively. Most patients were white (85.2%) and male (25.2%). Hospitalization rate was 55.6%, and five patients (18.5%) were admitted to the ICU, all of which subsequently died. Neither presence of comorbidities nor advanced age were related to lethality. Patients with immunosuppression modifications (p= 0.039) or isolated tacrolimus suspension (p= 0.006) were associated with increased mortality. CONCLUSION This study described COVID-19 infections in LT recipients of Latin-American populations. This group was not affected by common factors associated with higher lethality, as well as displaying a tendency to lower hospitalization rates. Our study concurred with previously reported evidence of a protective association of tacrolimus maintenance during treatment in LT recipients affected by COVID-19. Amid the COVID-19 pandemic, solid organ transplant centers have been subjected to a severe decline in the number of undertaken procedures, as well as with novel challenges in the follow-up and management of solid organ transplant (SOT) recipients. In this scenario, the consequences of infection by the SARS-CoV 2 virus in these patients is of particular concern, notably due to the perceived added risk of these patients related to immunosuppression and comorbidity burden. Current literature reports diverge on the impact of COVID-19 in liver transplant (LT) recipients. Some authors have observed increased lethality associated with older age and increased amount of comorbidities in these patients [1] [2] [3] [4] , while other reports, including meta-analyses, did not achieve such results. [5] [6] [7] A single study even reported a seemingly protective effect of immunosuppressive therapies upon lethality in SOT recipients. [2] As such, this study seeks to report the impact of COVID-19, disease characteristics, and progression in LT recipients, providing hypotheses of the pathogenesis of such infection in a Latin-American academic center. We designed this study as a historic cohort, analyzing patient records submitted by an online standardized questionnaire. The study included adult, LT recipient patients with suspected or confirmed COVID-19 who sought care between December 2019 and October 2021. The primary end-point was defined as COVID-related death, and follow-up was maintained until either death or the submission of data to analysis. We collected demographic, clinical, and laboratory data regarding presentation, disease progression, and outcome of the infection (survival, death). All participants consented to the collection of this data by agreeing to a standardized term approved by the institution's ethics committee. Statistical analysis was performed by using the SPSS program, version 23 (IBM, Armonk, NY, USA), with descriptive analysis and parametric or nonparametric comparative tests according to variable normality. Mann-Whitney Q was used for non-normal continuous variables while using t-Student and ANOVA tests for normal variables. The chi-squared test was used for normal and non-normal discrete binary variables and multinomial logistic regression for non-binary categorical variables. We included twenty-seven patients in the final analysis. All cases were confirmed by RT-PCR for SARS-CoV2. These cases represented a 3,5% incidence rate within our 752 LT recipients currently in follow-up. Demographic and clinical data on these cases is displayed in table 1. Mean follow up time was 92,04 days (SD +/-95,8 days). The mean age in our sample was 54 years old (SD +/-11 years), with a mean time from transplantation of 6.3 years (SD +/-5.4 years). Most patients were white (85.2%) and male (25.2%). Fifteen patients (55.6%) required inpatient treatment, with five subsequently admitted to the ICU. Five deaths were recorded in our sample, all from patients in the ICU. These represent a 33.4% lethality rate on hospitalized patients and an 18,5% lethality overall. All recorded deaths were due to acute COVID-19 complications. Detailed characteristics of the recorded deaths are displayed in table 2. Only two patients displayed liver enzyme elevations (AST and ALT of 195/221 and 151/162 in each case, respectively). Despite that, there were no reports of liver function alterations and no graft losses in our sample. Immunosuppression modifications correlated with increased mortality, with all deaths occurring within the 13 patients whose regimen had alterations (p= 0.039). Lastly, four deaths were reported in patients using tacrolimus at admission, accounting for a 23.52% mortality. Only one death was reported within the nine patients not using tacrolimus at admission. Such a difference did not correlate with mortality (p= 0.62). There was, however, an increase in mortality related to tacrolimus suspension after admission, compared to its maintenance, with no deaths in the former group and 3 in the latter (p= 0.006). In this study, we observed that, although the SARS-CoV2 infection in LT recipients mainly displayed similar characteristics to those reported in previous studies in the same populations, some crucial aspects, such as the association of greater lethality to advanced age and comorbidities [1] [2] [3] [4] 8, 9] , was not observed in our study. In our study, the hospitalization rate (55.6%) was not as high as reported in other studies, which displayed rates of up to 88% in LT recipients [8] [9] [10] . Unlike other reports in literature [2] [3] [4] [5] [10] [11] [12] , the lethality rate observed in our sample (18.51%) was quite elevated. Yet, our study has not found any causal factors that justify such increased lethality. While previous evidence indicates older age and the presence of comorbidities as factors associated with increased mortality in SOT recipients [1, 2, 4, 9, 13] , none of these variables displayed such correlations in our study. Nevertheless, similarly to a study by Coll et al., we found a tendency to lower lethality from the first wave of disease to the second, dropping from 42,8% to 10% between both peaks of infections. [3] In our study, 17 patients (62.96%) used tacrolimus at admission. Although the use of tacrolimus at admission was not associated with increased mortality, the discontinuation of tacrolimus therapy in users at admission was associated with higher mortality -a result in line with that reported by Belli et al. The results in this study must be interpreted accounting for its limitations. These are notably, the retrospective, non-controlled design and the use of patient records to extract information. These limitations may hinder the reproduction of results and require more complementary studies. Conversely, the novel population, the number of variables collected, and the inclusion of patients from all phases of the pandemic attest to the validity of our analysis. In conclusion, this study showed that LT recipients with COVID-19 in Latin America were not as affected by common factors associated with mortality and had lower hospitalization rates. Moreover, our study concurred with previously reported evidence suggesting a protective association of tacrolimus maintenance during treatment of these patients. COVID-19 in solid organ transplant: A multi-center cohort study Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave? Covid-19 in liver transplant recipients: the French SOT COVID registry Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study Impact of COVID-19 on liver transplant recipients-A systematic review and meta-analysis Clinical Characteristics, Hospitalization, and Mortality Rates of Coronavirus Disease 2019 Among Liver Transplant Patients in the United States: A Multicenter Research Network Study COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry COVID-19 in transplant recipients: The Spanish experience COVID-19 in an international European liver transplant recipient cohort Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients COVID-19 in Liver Transplant Recipients: An Initial Experience From the US Epicenter COVID-19 in Liver Transplant Recipients: A Systematic Review